FDA Approves Tavapadon as a Novel Treatment for Parkinson’s Disease
Adults diagnosed with Parkinson’s disease have a new therapeutic option following a recent regulatory decision by the U.S. Food and Drug Administration (FDA). Drug manufacturer AbbVie announced that the agency has approved tavapadon, marketed under the brand name Juvmo, to manage symptoms associated with the progressive neurological condition. The approval marks a significant milestone in neurology, introducing a distinct pharmacological approach to help patients and healthcare providers control motor symptoms while managing treatment side effects.
Tavapadon stands apart from existing medications within its drug class because it is the first oral selective D1/D5 dopamine agonist approved for Parkinson’s disease. While traditional dopamine agonists primarily target D2 and D3 receptors, tavapadon’s unique mechanism of action focuses on D1 and D5 receptors. According to drugmaker announcements and clinical trial data, this novel selectivity addresses a long-standing therapeutic need by giving physicians greater flexibility to tailor regimens to individual patient profiles and reduce reliance on escalating doses of oral levodopa.
The regulatory approval is supported by findings from a comprehensive clinical trial program known as the TEMPO studies. In the TEMPO-1 fixed-dose and TEMPO-2 flexible-dose trials, researchers evaluated tavapadon as a standalone monotherapy for individuals in the early stages of Parkinson’s disease. Participants receiving the medication experienced significant improvements in combined scores on the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) parts II and III at week 26 when compared against a placebo group. These specific score sections measure daily living activities and overall motor performance.
Additionally, the TEMPO-3 trial investigated tavapadon used alongside oral levodopa for patients with advanced Parkinson’s disease who experienced motor fluctuations. Results demonstrated that the adjunctive therapy significantly increased daily “on” time—periods when medication successfully controls symptoms—without causing troublesome dyskinesia at 27 weeks compared to placebo. Patients who chose to continue into the open-label TEMPO-4 extension study maintained sustained treatment efficacy for up to 85 weeks, according to AbbVie.
Principal TEMPO trial investigator Dr. Hubert Fernandez of the Cleveland Clinic Lerner College of Medicine noted in a news release that treating Parkinson’s has always required balancing dependable motor symptom control with tolerability. He emphasized that the introduction of a therapy selectively targeting D1 and D5 receptors provides a much-needed innovation for clinical practice.
Despite the positive clinical outcomes, medical experts emphasize that tavapadon carries potential side effects and safety considerations. During clinical evaluations, most adverse events were mild to moderate and non-serious. For patients taking the medication as monotherapy, reported side effects included nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth, and anxiety. When combined with oral levodopa, frequent adverse events involved nausea, dyskinesia, dizziness, headache, hallucinations, and orthostatic hypotension.
Prescribing guidelines and official product warnings indicate that the drug can cause lowered blood pressure, orthostatic hypotension, and new or worsening dyskinesia. Furthermore, the medication may induce impulse control issues, compulsive behaviors, or psychotic-like symptoms and hallucinations. Physicians may need to adjust doses or discontinue treatment if these psychological or behavioral complications arise. AbbVie stated that the medication will be supplied in various tablet strengths, along with a titration pack, and is scheduled to become available to patients in the United States.
Source: MedPage Today
